Oriola Oyj Q2 2025 Earnings | 07/18/2025

About this video

Oriola Oyj released its Q2 2025 results on July 18, 2025, reporting strong sales growth but lower profitability due to high costs and significant one-off items. Net sales climbed by 12% year-over-year to EUR 494 million, driven by robust performance in both the Distribution and Wholesale segments. Sales margin improved by 6% to EUR 42.2 million, with the Distribution segment seeing especially notable gains supported by new customer wins and solid growth in Sweden. Adjusted EBITDA rose slightly to EUR 8.1 million compared to EUR 8.0 million in Q2 2024, reflecting better efficiency despite inflationary pressures and temporary increases in storage and logistics costs. The Distribution segment’s net sales were up 11% to EUR 398 million, with profitability improving 35% year-over-year; invoicing growth and new customer onboarding offset higher operating costs. The Wholesale segment delivered 18% net sales growth to EUR 96 million, propelled by strong demand and expanding parallel imports in Sweden. However, segment profit was negatively affected by increased personnel expenses and an unfavorable product mix. Profit for the quarter was burdened by EUR 6.5 million in adjusting items, including ERP-related implementation costs and a EUR 2.8 million loss from the sale of the dose dispensing business in Sweden. As a result, Oriola reported a net loss of EUR 5.6 million, with loss per share at EUR 0.03, compared to a profit of EUR 2.0 million a year ago. Despite these headwinds, free cash flow for the first half improved to EUR 20.8 million, thanks to better working capital management. Kronans Apotek, Oriola’s joint venture pharmacy business in Sweden, continued to expand its e-commerce footprint with 44% sales growth in the channel while brick-and-mortar sales remained steady. High costs impacted the joint venture’s results and, consequently, Oriola’s share of profit from associates remained negative. Looking forward, management maintains its guidance for improved adjusted EBITDA in the second half of 2025, expecting ongoing cost-efficiency measures and the stabilization of investment projects—particularly the ERP rollout—to contribute positively. The company’s strong market position in both Sweden and Finland, successful onboarding of new clients, and continued growth in digital and advisory services are expected to support results as Oriola advances its transformation strategy. About Inside Ticker: For expert financial analysis, real-time earnings breakdowns, and the latest updates on Oriola Oyj and the broader Nordic health sector, follow Inside Ticker and visit InsideTicker.com for in-depth coverage and insights. Hashtags: #OriolaOyj #Q22025 #Earnings #FinancialResults #Distribution #Wholesale #NetSales #Profitability #ERP #KronansApotek #HealthSector #ECommerce #Sweden #Finland #Pharmaceuticals #CashFlow #DigitalHealth #Transformation #InsideTicker #BusinessUpdate #ShareholderReturns #QuarterlyResults #MarketUpdate #GrowthStrategy #NordicMarkets #HealthInnovation #Logistics #Efficiency #InvestorUpdate #Q2Results